ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

CORRECT: Lilly, Amylin, Alkermes Diabetes Treatment Misses Primary Endpoints

("Lilly, Amylin, Alkermes Diabetes Treatment Misses Primary Endpoints," at 8:31 a.m. EST, misstated that Bydureon was approved in 2005 in the sixth paragraph. The correct version follows: ) DOW JONES NEWSWIRES An investigational drug to treat Type 2 diabetes under development by Eli Lilly & Co. (LLY), Amylin Pharmaceuticals Inc. (AMLN) and Alkermes Inc. (ALKS) failed to meet primary endpoints in a 26-week study. Lilly shares were down 33 cents at $33.95 in recent premarket trading, while Alkermes and Amylin were halted ahead of the announcement. They closed Wednesday at $14.10 and $15.01, respectively. The treatment, Bydureon, was less effective in reducing blood sugar levels than Victoza, an injectible diabetes treatment made by Novo Nordisk A/S (NVO, NOVO-B.KO). However, Victoza patients reported more frequent adverse reactions. The Food and Drug Administration had requested further data on Bydureon during October. The companies plan to submit a complete response in the second half of this year. Lilly's outlook has been shaky because it faces a wave of patent expirations that will expose its best-selling drugs to generic competition in coming years. Compounding its challenges, Lilly has suffered a series of research and regulatory setbacks that have hampered efforts to bring new products to market to replace the lost revenue. Bydureon is a long-acting version of already-approved diabetes drug Byetta, which has been available in the U.S. since June 2005. "While this study did not meet its primary endpoint, these results reinforce the important role" of the drug class in treating Type 2 diabetes, said Gwen Krivi, vice president product development at Lilly's diabetes unit. Evaluation of the data continue, and the companies plan to submit a full study for publication. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Alkermes (ALKS)
11/24/201517:46:22Statement of Changes in Beneficial Ownership (4)
11/24/201517:18:10Statement of Changes in Beneficial Ownership (4)
11/12/201517:21:39Statement of Changes in Beneficial Ownership (4)
11/12/201517:20:20Statement of Changes in Beneficial Ownership (4)
11/11/201516:00:00Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2...
11/04/201517:47:01Statement of Changes in Beneficial Ownership (4)
11/04/201517:42:39Statement of Changes in Beneficial Ownership (4)
11/04/201517:41:15Statement of Changes in Beneficial Ownership (4)
11/04/201517:37:19Statement of Changes in Beneficial Ownership (4)
11/03/201516:00:00Alkermes’ Corporate Presentation to Be Webcast at the Credit S...
10/31/201503:53:03Alkermes' (ALKS) CEO Richard Pops on Q3 2015 Results - Earnings...
10/30/201517:28:57Statement of Changes in Beneficial Ownership (4)
10/29/201508:08:11Quarterly Report (10-q)
10/29/201507:06:49Current Report Filing (8-k)
10/29/201507:01:00Alkermes plc Reports Third Quarter 2015 Financial Results
10/29/201507:00:00Alkermes Announces Positive Clinical Trial Results & Streamlined...
10/23/201517:29:52Statement of Changes in Beneficial Ownership (4)
10/22/201516:00:00Alkermes to Host Conference Call to Discuss Third Quarter 2015...
10/16/201509:48:53Current Report Filing (8-k)
10/14/201517:30:55Statement of Changes in Beneficial Ownership (4)

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations